Population Pharmacokinetics and Pharmacodynamics of Bezlotoxumab in Adults with Primary and Recurrent Clostridium difficile Infection

The fully human monoclonal antibody bezlotoxumab is indicated for preventing the recurrence of Clostridioides difficile (formerly Clostridium difficile) infection (CDI) in adults who receive antibacterial treatment for CDI and who are at high risk for a CDI recurrence. The efficacy and safety of 10-...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Antimicrob Agents Chemother
Prif Awduron: Yee, Ka Lai, Kleijn, Huub Jan, Kerbusch, Thomas, Matthews, Randolph P., Dorr, Mary Beth, Garey, Kevin W., Wrishko, Rebecca E.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Microbiology 2019
Pynciau:
Clinical Therapeutics
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6355577/
https://ncbi.nlm.nih.gov/pubmed/30455246
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01971-18
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg